These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12040294)

  • 21. Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential followed up by paclitaxel. A phase II study.
    Elling D; Eggemann H; Kümmel S; Breitbach P; Kohls A; Morack G; Schlosser H; Krocker J
    Breast; 2003 Jun; 12(3):208-11. PubMed ID: 14659328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An EORTC phase I study of epirubicin in combination with fixed doses of cyclophosphamide and infusional 5-fu (CEF-infu) as primary treatment of large operable or locally advanced/inflammatory breast cancer.
    Bonnefoi H; Biganzoli L; Cufer T; Mauriac L; Hamilton A; Schaefer P; Piccart M
    Breast Cancer Res Treat; 2001 Nov; 70(1):55-63. PubMed ID: 11768362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors of survival in pathologic incomplete response patients with locally advanced breast cancer after neoadjuvant chemotherapy.
    Huang O; Jiang M; Chen XS; Wu JY; Chen WG; Li YF; Shen KW
    Cell Biochem Biophys; 2015 Mar; 71(2):1181-90. PubMed ID: 25427887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months.
    Huang O; Chen C; Wu J; Chen S; Chen X; Liu G; Hu Z; Lu J; Wu J; Shao Z; Shen Z; Shen K
    BMC Cancer; 2009 Oct; 9():375. PubMed ID: 19845944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study.
    Serin D; Verrill M; Jones A; Delozier T; Coleman R; Kreuser ED; Mross K; Longerey B; Brandely M
    Br J Cancer; 2005 Jun; 92(11):1989-96. PubMed ID: 15928659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. First-line treatment with epirubicin and vinorelbine in metastatic breast cancer.
    Vici P; Colucci G; Gebbia V; Amodio A; Giotta F; Belli F; Conti F; Gebbia N; Pezzella G; Valerio MR; Brandi M; Pisconti S; Durini E; Giannarelli D; Lopez M
    J Clin Oncol; 2002 Jun; 20(11):2689-94. PubMed ID: 12039931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I studies of fluorouracil, doxorubicin and vinorelbine without (FAN) and with (SUPERFAN) folinic acid in patients with advanced breast cancer.
    Goss PE; Fine S; Gelmon K; Rudinskas L; Ottaway J; Myles J; James K; Paul K; Rodgers A; Pritchard KI
    Cancer Chemother Pharmacol; 1997; 41(1):53-60. PubMed ID: 9443614
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multidisciplinary therapy of locally far-advanced or inflammatory breast cancer with fixed perioperative sequence of epirubicin, vinorelbine, and Fluorouracil chemotherapy, surgery, and radiotherapy: long-term results.
    Ardavanis A; Scorilas A; Tryfonopoulos D; Orphanos G; Missitzis I; Karamouzis M; Chrysochoou M; Sotiropoulou A; Arnogiannaki N; Ioannidis G; Pissakas G; Rigatos G
    Oncologist; 2006 Jun; 11(6):563-73. PubMed ID: 16794236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial.
    von Minckwitz G; Kümmel S; Vogel P; Hanusch C; Eidtmann H; Hilfrich J; Gerber B; Huober J; Costa SD; Jackisch C; Loibl S; Mehta K; Kaufmann M;
    J Natl Cancer Inst; 2008 Apr; 100(8):542-51. PubMed ID: 18398097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer.
    Vici P; Foggi P; Colucci G; Capomolla E; Brandi M; Giotta F; Gebbia N; Di Lauro L; Valerio MR; Paoletti G; Belli F; Pizza C; Giannarelli D; Lopez M
    Anticancer Res; 2005; 25(2B):1309-14. PubMed ID: 15865083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neoadjuvant sequential epirubicin and docetaxel followed by surgery-radiotherapy and post-operative docetaxel or gemcitabine/vinorelbine combination based on primary response: a multimodality approach for locally advanced breast cancer.
    Kountourakis P; Missitzis I; Doufexis D; Zobolas V; Pissakas G; Arnogiannaki N; Maliou S; Sotiropoulou A; Ardavanis A
    J Cancer Res Clin Oncol; 2011 Feb; 137(2):221-8. PubMed ID: 20387073
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II trial of a combination of vinorelbine, cyclophosphamide and 5-fluorouracil in the treatment of advanced breast cancer.
    Ardavanis A; Extra JM; Espié M; Cuvier C; Marty M
    In Vivo; 1998; 12(5):559-62. PubMed ID: 9827368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with a nonanthracycline regimen in advanced breast cancer: vinorelbine, cyclophosphamide, and 5-fluorouracil with folinic acid.
    Turpin F; Lluch A; Closon MH; Gruia G; Llombart A; Fernandez R; Delgado FM; Biville F
    Am J Clin Oncol; 1999 Apr; 22(2):196-8. PubMed ID: 10199461
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.
    Smith JW; Buyse ME; Rastogi P; Geyer CE; Jacobs SA; Patocskai EJ; Robidoux A; Conlin AK; Ansari B; Keogh GP; Stella PJ; Gross HM; Lord RS; Polikoff JA; Mauquoi C; Mamounas EP; Swain SM; Wolmark N
    Clin Breast Cancer; 2017 Feb; 17(1):48-54.e3. PubMed ID: 27693116
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Paclitaxel combinations as front-line and salvage chemotherapy regimens in advanced breast cancer.
    Conte PF; Baldini E; Michelotti A; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Giannessi PG; Gentile A
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):39-42. PubMed ID: 8996597
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer.
    Abrahamova J; Wagnerova M; Kubala E; Malec V; Simova E; Sirakova I; Pavlikova E; Machova D; Kocak I; Pavlikova I; Tuma P; Prausova J; Kroslakova D; Van Praagh I
    Oncologist; 2001; 6(4):347-52. PubMed ID: 11524553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Taxane and anthracycline based neoadjuvant chemotherapy for locally advanced breast cancer: institutional experience.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
    Asian Pac J Cancer Prev; 2014; 15(5):1989-92. PubMed ID: 24716923
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel plus vinorelbine as salvage chemotherapy in advanced breast cancer: a phase II study.
    Rodríguez J; Calvo E; Cortes J; Santisteban M; Perez-Calvo J; Martínez-Monge R; Brugarolas A; Fernández-Hidalgo O
    Breast Cancer Res Treat; 2002 Nov; 76(1):47-56. PubMed ID: 12408375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paclitaxel in combination with vinorelbine in pretreated advanced breast cancer patients.
    Michelotti A; Gennari A; Salvadori B; Giannessi PG; Baldini E; Tibaldi C; Da Prato M; Conte PF
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):38-40. PubMed ID: 8893898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.